Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Decibel Therapeutics, Inc.
Report date September 25, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 1
1 source rowRow 1 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 5,000 unvested Company RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2032-06-16 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.42 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that is greater than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),
F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.
F3: Includes 5,000 unvested Company RSUs.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.
F6: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that is greater than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment was cancelled with no consideration payable in respect thereof.
Prevail Therapeutics Inc.
Report date January 22, 2021 · Filed January 26, 2021
Section 16 reporting ended · disclosed 2021-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.11 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-22 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001824280-26-000005 · form4-06152026_040603.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 8,000 | $5.78 | $46,240.00 |
DisclosureSEC source: 0001824280-26-000004 · form4-05132026_040507.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,405 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 20:16 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 8,000 | $6.20 | $49,600.00 |
DisclosureSEC source: 0001824280-26-000003 · form4-04142026_080436.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,405 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:31 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 8,000 | $5.67 | $45,360.00 |
DisclosureSEC source: 0001824280-26-000002 · form4-03122026_040329.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,405 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted December 8, 2025. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $5.02 | $20,657.30 |
DisclosureSEC source: 0001824280-26-000001 · form4-01022026_040103.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,405 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $4.47 | $18,394.05 |
DisclosureSEC source: 0001824280-25-000007 · form4-12032025_041210.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,290 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $4.43 to $4.50, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| October 30, 2025 Filed Oct 31, 2025 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $3.17 | $13,044.55 |
DisclosureSEC source: 0001824280-25-000006 · form4-10312025_041004.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,175 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.15 o $3.20, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $3.05 | $12,550.75 |
DisclosureSEC source: 0001824280-25-000005 · form4-10022025_081058.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,060 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.035 o $3.08, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $2.09 | $8,600.35 |
DisclosureSEC source: 0001415889-25-023679 · form4-09042025_040906.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,945 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.06 to $2.115, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| July 30, 2025 Filed Aug 1, 2025 20:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $2.43 | $9,999.45 |
DisclosureSEC source: 0001415889-25-020861 · form4-08012025_040819.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,830 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.37 to $2.44, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:55 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 4,115 | $2.46 | $10,122.90 |
DisclosureSEC source: 0001415889-25-018724 · form4-07012025_080710.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,715 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 17, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.45 to $2.47, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:22 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001415889-25-016258 · form4-06092025_080607.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 23:12 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $5.33 | $17,056.00 |
DisclosureSEC source: 0001415889-24-028316 · form4-12042024_111242.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,600 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $5.25 to $5.53, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $5.97 | $19,104.00 |
DisclosureSEC source: 0001415889-24-024384 · form4-10022024_041010.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,400 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $5.765 to $6.16, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:34 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $5.48 | $17,536.00 |
DisclosureSEC source: 0001415889-24-022785 · form4-09042024_040906.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,200 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $5.38 to $5.70, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 23:53 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $6.24 | $19,968.00 |
DisclosureSEC source: 0001415889-24-020789 · form4-08052024_110859.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $6.07 to $6.455, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:43 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $5.00 | $16,000.00 |
DisclosureSEC source: 0001415889-24-018985 · form4-07022024_090733.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,800 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $4.83 to $5.145, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:41 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0001415889-24-016103 · form4-06082024_010632.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:23 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $4.83 | $15,459.20 |
DisclosureSEC source: 0001415889-24-015560 · form4-06052024_080641.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,600 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $4.60 to $5.01, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $4.68 | $14,982.40 |
DisclosureSEC source: 0001415889-24-012154 · form4-05032024_040501.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,400 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $4.49 to $4.84, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 23:17 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 3,200 | $6.07 | $19,411.20 |
DisclosureSEC source: 0001415889-24-010667 · form4-04102024_110457.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted January 4, 2024. F2 · price: This transaction was executed in multiple trades in prices ranging from $5.82 to $6.20, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:32 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $8.42 | Not disclosed |
DisclosureSEC source: 0000899243-23-019498 · doc4.xml · derivative · entry 4 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-06-01 F6 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that is greater than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment was cancelled with no consideration payable in respect thereof. F6 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that is greater than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment was cancelled with no consideration payable in respect thereof. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:32 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $4.78 | Not disclosed |
DisclosureSEC source: 0000899243-23-019498 · doc4.xml · derivative · entry 3 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2033-06-12 F5 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:32 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0000899243-23-019498 · doc4.xml · derivative · entry 2 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F4 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:32 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019498 · doc4.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · shares: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3 · shares: Includes 5,000 unvested Company RSUs. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · price: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:42 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0000950170-23-027996 · ownership.xml · derivative · entry 2 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-12 F3 · derivative.exercise_date: This option was granted on June 13, 2023 for 5,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:42 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027996 · ownership.xml · nonDerivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Consists of shares of the Issuer's common stock issuable under 5,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest in full on the one year anniversary of the date of grant of the RSUs (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the RSUs), subject to the reporting person's continued service. F2 · balance_after: Includes 5,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:44 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001610717-23-000140 · form4.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 18:54 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-22-023470 · doc4.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option was granted on June 17, 2022 for 10,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:28 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001567619-22-012774 · doc1.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 16:45 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0000899243-21-021812 · doc4.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option was granted on June 2, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:10 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001567619-21-011720 · doc1.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:53 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001567619-21-002497 · doc1.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from February 5, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:17 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $11.11 | $0.00 |
DisclosureSEC source: 0001209191-21-005449 · doc4.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 08:30 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $11.11 | $0.00 |
DisclosureSEC source: 0001209191-20-050091 · doc4.xml · derivative · entry 1 Carson William H. · CIK 0001824280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: The shares underlying the option will vest in 36 equal monthly installments beginning on October 9, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.